Your browser doesn't support javascript.
Development of an automated chemiluminescence assay system for quantitative measurement of multiple anti-SARS-CoV-2 antibodies
Sousuke Kubo; Norihisa Ohtake; Kei Miyakawa; Sundararaj Stanleyraj Jeremiah; Yutaro Yamaoka; Kota Murohashi; Eri Hagiwara; Takahiro Mihara; Atsushi Goto; Etsuko Yamazaki; Takashi Ogura; Takeshi Kaneko; Takeharu Yamanaka; Akihide Ryo.
  • Sousuke Kubo; Yokohama City University Graduate School of Medicine
  • Norihisa Ohtake; Yokohama City University
  • Kei Miyakawa; Yokohama City University Graduate School of Medicine
  • Sundararaj Stanleyraj Jeremiah; Yokohama City University Graduate School of Medicine
  • Yutaro Yamaoka; Yokohama City University Graduate School of Medicine
  • Kota Murohashi; Kanagawa Cardiovascular and Respiratory Center
  • Eri Hagiwara; Kanagawa Cardiovascular and Respiratory Center
  • Takahiro Mihara; Yokohama City University Graduate School of Data Science
  • Atsushi Goto; Yokohama City University Graduate School of Data Science
  • Etsuko Yamazaki; Yokohama City University Hospital
  • Takashi Ogura; Kanagawa Cardiovascular and Respiratory Center
  • Takeshi Kaneko; Yokohama City University Graduate School of Medicine
  • Takeharu Yamanaka; Yokohama City University Graduate School of Medicine
  • Akihide Ryo; Yokohama City University Graduate School of Medicine
Preprint in English | medRxiv | ID: ppmedrxiv-20225805
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
ObjectiveSerological tests for COVID-19 have been instrumental in studying the epidemiology of the disease. However, the performance of the currently available tests is plagued by the problem of variability. We have developed a high-throughput serological test capable of simultaneously detecting total immunoglobulins (Ig) and immunoglobulin G (IgG) against two of the most immunologically relevant SARS-CoV-2 antigens, nucleocapsid protein (NP) and spike protein (SP) and report its performance in detecting COVID-19 in clinical samples. MethodsWe designed and prepared reagents for measuring NP-IgG, NP-Total Ig, SP-IgG, and SP-Total Ig (using N-terminally truncated NP ({Delta}N-NP) or receptor-binding domain (RBD) antigen) on the advanced chemiluminescence enzyme immunoassay system TOSOH AIA-CL. After determining the basal thresholds based on 17 sera obtained from confirmed COVID-19 patients and 600 negative sera. Subsequently, the clinical validity of the assay was evaluated using independent 202 positive samples and 1,000 negative samples from healthy donors. ResultsAll of the four test parameters showed 100% specificity individually (1,000/1,000; 95%CI, 99.63-100). The sensitivity of the assay increased proportionally to the elapsed time from symptoms onset, and all the tests achieved 100% sensitivity (153/153; 95%CI, 97.63-100) after 13 days from symptoms onset. NP-Total Ig was the earliest to attain maximal sensitivity among the other antibodies tested. ConclusionOur newly developed serological testing exhibited 100% sensitivity and specificity after 13 days from symptoms onset. Hence, it could be used as a reliable method for accurate detection of COVID-19 patients and to evaluate seroprevalence and possibly for surrogate assessment of herd immunity.
Full text: Available Collection: Preprints Database: medRxiv Language: English Year: 2020 Document Type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Language: English Year: 2020 Document Type: Preprint